10 research outputs found
Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy
Context: The therapeutic strategy in intermediate risk (IR) non-muscle invasive bladder cancer (NMIBC) recurring after intravesical therapy (IT) is not well defined. Most patients are usually retreated by Bacillus Calmette-Guerin (BCG). Aims: To evaluate the efficacy of intravesical chemotherapy (ICH) given at recurrence after the first cycle of ICH in IR-NMIBC recurring 6 months or later. Settings and Design: Retrospective analysis of the efficacy of ICH given after previous IT. Materials and Methods: The clinical files of IR-NMIBC patients recurring later than 6 months after transurethral resection (TUR) and IT and retreated by IT were reviewed. The patients should be at intermediate risk both initially and at the first recurrence. BCG should have been given at full dose. Cytology and cystoscopy were performed 3 monthly for 2 years and then 6 monthly. Statistical Analysis: The RFS was estimated by the Kaplan-Meier method and the differences between treatment groups were compared by log-rank test. Mann Whitney U-test was used to compare the parameters\u2032 distribution for median time to recurrence. Multivariate Cox proportional hazards models were used. Results: The study included 179 patients. The first IT was ICH in 146 (81.6%) and BCG in 33 (18.4%), re-IT was ICH in 112 (62.6%) and BCG in 67 (37.4%) patients. Median time to recurrence was 18 and 16 months after first and second IT (P = 0.32). At 3 years, 24 (35.8%) and 49 (43.8%) patients recurred after BCG and ICH, respectively (P = 0.90). No difference in RFS was found between BCG and ICH given after a first cycle of ICH (P = 0.23). Conclusions: Re-treatment with ICH could represent a legitimate option to BCG in patients harboring IR-NMIBC recurring after TUR and previous ICH. Prospective trials are needed
CHOICE OF ADJUVANT INTRAVESICAL THERAPY IN RECURRING INTERMEDIATE-RISK NMI-BC
Objective: The therapeutic strategy for patients affected by
intermediate risk non-muscle invasive bladder cancer (NMIBC)
recurring after intravesical therapy is not definitively
established. Only few studies have been published on secondline
intravesical therapy. BCG is advocated when intravesical
chemotherapy fails and is often repeated. On the other hand,
some patients that suffer recurrence repeat intravesical
chemotherapy. A retrospective analysis of 179 intermediaterisk
patients submitted to second-line intravesical therapy is
reported. Patients and Methods: The clinical files of patients
affected by intermediate risk NMI-BC and submitted to
second-line adjuvant intravesical therapy were reviewed.
Patients not receiving at least six instillations of BCG or
intravesical chemotherapy after the first diagnosis and again
after the transurethral resection (TUR) of the first recurrence
were excluded. Only mitomycin c and epirubicin were
accepted as chemotherapy. Only patients with intermediaterisk
tumors with a recurrence-risk score between 5 and 9
according to the EORTC risk tables and in absence of Tis were
selected. A multivariate analysis was performed for
recurrence-free survival (RFS) and progression, considering
first line intravesical therapy (BCG versus ICH), previous
recurrence-free interval, tumor T category, G grade,
multiplicity, second-line intravesical therapy (BCG versus
ICH) and maintenance regimen. Results: The study included
179 patients. Chemotherapy was administered as first-line
therapy in 131 (73.2%) and BCG in 48 (26.8%) patients.
Second-line therapy was represented by BCG in 83 (46.4%)
and chemotherapy in 96 (53.6%) patients, with maintenance
of at least 12 months in 31% and 38% of patients, respectively.
Of the 48 patients previously treated by BCG, 40 (83.3%)
received BCG again, while of the 131 previously treated by
chemotherapy, 88 (67.2%) repeated it and 43 (32.8%) received
BCG. At a median follow-up of 29 months after the second
TUR, 65 (36.3%) patients experienced recurrence, 25 (30.1%)
and 40 (41.7%) after BCG and chemotherapy, respectively.
Thirteen patients showed progression at a median interval of
19 months. At multivariate analysis, no statistically significant
correlation was detected. Surprisingly, no statistical difference
emerged in terms of recurrence-free interval between first- and
second-line therapy and between BCG and chemotherapy as
second-line therapy at recurrence after chemotherapy (p=0.28)
Conclusion: Almost 65% of patients experiencing recurrence
after intravesical chemotherapy received intravesical therapy
again. No difference in efficacy was detected between firstand
second-line therapies or between BCG and chemotherapy
given at recurrence after chemotherapy
Can we ameliorate the compliance to intravesical bcg maintenance? Analysis of the causes of treatment interruption in 160 consecutive patients.
432 RE-TREATMENT BY INTRAVESICAL THERAPY IN RECURRING PATIENTS AFFECTED BY INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMI-BC)
BIOMARKERS OF UROTHELIAL DAMAGE IN PATIENTS TREATED BY ADJUVANT INTRAVESICAL THERAPY
Introduction/Aim: Chemotherapy or BCG given intravesically
to prevent recurrence after transurethral resection (TUR) of
non-muscle invasive bladder cancer (NMI-BC) cause
frequent, sometime severe, local toxicity. As a consequence,
many patients do not complete the planned treatment (1). A
major challenge for the urologists is to identify an early biomarker of urothelial damage to recognize and prevent local
toxicity improving patient’s compliance. The purpose of our
research was to investigate the relation between urothelial
injury by intravesical treatment and the expression of
potential biomarkers in urine and/or in barbotage solution.
The urinary HB-EGF expression in interstitial cystitis has
been analyzed by a few studies (2, 3). As a preliminary step,
the variations of Fibronectin (FN), Epidermal Growth Factor-
Receptor (EGF-R) and Heparin-binding Epidermal Growth
Factor-like Growth Factor (HB-EGF) during intravesical
therapy and after the administration of a solution with the
potential role of urothelial repairing (hyaluronic acid and
chondroitin sulphate) were investigated. Patients and
Methods: the toxicity of intravesical therapy with mitomycin,
epirubicin or BCG was classified in 3 grades (absent,
moderate, severe). Urine and bladder washing solution during
intravesical therapy in 55 patients after NMI-BC TUR and in
10 healthy controls for a total of 200 samples were collected.
Total cellular RNA was isolated from the cell pellet using
miRNeasy Mini Kit (Qiagen®). FN and EGF-R gene
expression by Real Time quantitative PCR were analyzed.
The expression of HB-EGF was measured in urine samples
by ELISA (Abcam®). Results: In barbotage samples the FN
gene expression and the EGF-R levels in our patients were
respectively increased a median of 4.7 fold and decreased of
0.9 fold compared to controls. Before intravesical therapy and
in absence of local toxicity, gene expression increased 1.9
fold for FN and 1.1 fold for EGF-R. In contrast, in patients
with local toxicity due to intravesical therapy, the FN gene
expression levels increased to a median of 5.82 fold, while
EGF-R remained unchanged. The administration of
hyaluronic acid and chondroitin sulphate solution decreased
the mean FN gene expression from 3 to 0.6 fold, with
concomitant symptomatic relief. HB-EGF protein median
urine levels were 25.7 pg/ml in 13 patients before intravesical
therapy and 18.9 pg/ml in 5 healthy controls. No significant
variations in relation to the local toxicity. During therapy
median HB-EGF protein levels in urine varied from 21.6
pg/ml in absence of toxicity to 25.7 pg/ml in case of severe
toxicity to 18.5 pg/ml after hyaluronic acid and chondroitin
sulphate solution. Preliminarily, the observed variations of
HB-EGF, increasing no more than 1.2 fold compared to
healthy controls, do not seem possible marker of urothelial
damage. Discussion and Conclusion: EGF-R gene and HBEGF
expressions do not seem to vary significantly in relation
to local toxicity due to intravesical therapy. FN gene is
overexpressed in presence of urothelial damage significantly
reduced by intravesical hyaluronic acid and chondroitin
sulphate solution administration, according with symptoms
relief
PRELIMINARY DATA ON PSA CHANGES DURING INTRAVESICAL THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER
Introduction/Aim: Many factors can cause an increase of PSA
independently from the presence of prostate cancer . The
objective was to evaluate the fluctuation of the serum levels of
PSA during adjuvant intravesical chemotherapy or
immunotherapy. An increase of PSA due to intravesical BCG
and up to 3 months later has been reported (1). Patients and
Methods: Patients treated with intravesical chemotherapy or
immunotherapy for non- muscle invasive bladder cancer (NMIBC)
were entered in the study. Serum samples were collected
before starting intravesical therapy, during therapy (within 3rd
and 6th instillation) and 30 days after the end of the 6-week
induction regimen and during maintenance regimen when
given. Patients with urinary tract infections, history of chronic
prostatitis, elevated PSA before starting intravesical therapy,
palpable prostate nodule or prostate cancer were not included.
Results: Forty-five patients were studied, 34 receiving
chemotherapy and 11 BCG. Thirty-three patients completed the
induction regimen and in 12 more patients the research is
ongoing. Out of the 33 evaluable patients, 23 received
chemotherapy (mitomycin or epirubicin), while 10
immunotherapy (BCG Connaught). The pre-induction PSA
mean level was 2.9 ng/ml.We observed a median PSA increase
of 33,5% (p<0.0001) during therapy, in 18 (54.5%) patients. Twelve patients (36.3%) showed a median PSA decrease of
31.4% (p=0.3638). In two patients only (6%) PSA remained
unchanged.We also observed a median increase of serum PSA
levels of 87.4% at one month after the end of induction
regimen. No significant difference between serum PSA level
fluctuations induced by chemotherapy or BCG was detected:
median increases during therapy and 30 days after the end were
91.7% and 149, 7% and 91.7% and 133% respectively
(p<0.001). Discussion and Conclusion: Our preliminary study
shows a clinically relevant increase of serum PSA levels in men
undergoing both adjuvant intravesical BCG or chemotherapy.
We confirm the results of the few studies reporting the increase
of PSA during intravesical therapy with BCG or chemotherapy
(2). The above mentioned variations should be considered
when selecting patients undergoing prostate biopsy
A PROSPECTIVE STUDY ON THE INFLUENCE ON RECURRENCE OF QUITTING CIGARETTE SMOKING AT DIAGNOSIS OF PRIMARY NON MUSCLE INVASIVE BLADDER CANCER
Cigarette smoking is a
known risk factor for bladder cancer (BC). Even if there is evidence that
quitting decreases the incidence of BC it is still object of debate if
quitting at first diagnosis could influence the outcome of primary non
muscle invasive bladder cancer (NMIBC) reducing the risk of further
recurrence. The aim of the present prospective study is to evaluate the
outcome of smokers affected by primary NMI-BC in relation to their
smoking habit after diagnosis